{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:49:07Z","timestamp":1791571747961,"version":"4.3.4"},"reference-count":72,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.clml.2022.05.003","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T17:12:45Z","timestamp":1653325965000},"page":"760-773","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Real World Adherence to and Persistence With Oral Oncolytics in Multiple Myeloma: A Systematic Review and Meta-analysis"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8440-7446","authenticated-orcid":false,"given":"Abdallah Y.","family":"Naser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Ofori-Asenso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safaa Al","family":"Awawdeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Qadus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Alwafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0131-623X","authenticated-orcid":false,"given":"Danny","family":"Liew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.05.003_bib0001","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1038\/leu.2016.380","article-title":"Trends in overall survival and costs of multiple myeloma, 2000-2014","volume":"31","author":"Fonseca","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.05.003_sbref0002","series-title":"Multiple Myeloma, Globocan 2020","year":"2020"},{"key":"10.1016\/j.clml.2022.05.003_bib0003","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clml.2022.05.003_bib0004","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: a unique malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clml.2022.05.003_bib0005","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/leu.2017.329","article-title":"Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond","volume":"32","author":"Chim","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.05.003_bib0006","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s13045-020-00980-5","article-title":"Emerging agents and regimens for multiple myeloma","volume":"13","author":"Yang","year":"2020","journal-title":"J. Hematol. Oncol"},{"key":"10.1016\/j.clml.2022.05.003_bib0007","doi-asserted-by":"crossref","first-page":"e674","DOI":"10.1200\/JOP.18.00085","article-title":"Collaborative physician-pharmacist-managed multiple myeloma clinic improves guideline adherence and prevents treatment delays","volume":"14","author":"Sweiss","year":"2018","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.clml.2022.05.003_bib0008","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.clml.2018.01.006","article-title":"Assessing the effect of adherence on patient-reported outcomes and out of pocket costs among patients with multiple myeloma","volume":"18","author":"Gupta","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2022.05.003_bib0009","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1634\/theoncologist.2018-0724","article-title":"Patient-reported factors in treatment satisfaction in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"24","author":"Chari","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2022.05.003_bib0010","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/10428194.2020.1827253","article-title":"Trends in the multiple myeloma treatment landscape and survival: a U.S. analysis using 2011-2019 oncology clinic electronic health record data","volume":"62","author":"Braunlin","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.05.003_sbref0011","series-title":"Notices","year":"2022"},{"key":"10.1016\/j.clml.2022.05.003_bib0012","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/annonc\/mdp595","article-title":"Treatment of cancer with oral drugs: a position statement by the Spanish society of medical oncology (SEOM)","volume":"21","author":"Colomer","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2022.05.003_bib0013","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1634\/theoncologist.2015-0405","article-title":"A systematic review of adherence to oral antineoplastic therapies","volume":"21","author":"Greer","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2022.05.003_bib0014","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/ecc.12124","article-title":"Adherence to oral antineoplastic agents by cancer patients: definition and literature review","volume":"23","author":"Bassan","year":"2014","journal-title":"Eur J Cancer Care"},{"key":"10.1016\/j.clml.2022.05.003_bib0015","doi-asserted-by":"crossref","first-page":"304","DOI":"10.4065\/mcp.2010.0575","article-title":"Medication adherence: WHO cares?","volume":"86","author":"Brown","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2022.05.003_bib0016","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1547-5069.2003.tb00001.x","article-title":"Adherence to long-term therapies: evidence for action","volume":"35","author":"Burkhart","year":"2003","journal-title":"J Nurs Scholarsh"},{"key":"10.1016\/j.clml.2022.05.003_bib0017","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.clml.2022.05.003_bib0018","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"Jama"},{"key":"10.1016\/j.clml.2022.05.003_bib0019","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Green","year":"2005"},{"key":"10.1016\/j.clml.2022.05.003_bib0020","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/bcp.12194","article-title":"What are validated self-report adherence scales really measuring?: a systematic review","volume":"77","author":"Nguyen","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clml.2022.05.003_bib0021","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","article-title":"Medication compliance and persistence: terminology and definitions","volume":"11","author":"Cramer","year":"2008","journal-title":"Value Health"},{"key":"10.1016\/j.clml.2022.05.003_bib0022","doi-asserted-by":"crossref","first-page":"e3350","DOI":"10.1002\/dmrr.3350","article-title":"Poor adherence and persistence to sodium glucose co-transporter 2 inhibitors in real-world settings: Evidence from a systematic review and meta-analysis","volume":"37","author":"Ofori-Asenso","year":"2021","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.clml.2022.05.003_bib0023","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/dom.13160","article-title":"Comparison of medication adherence and persistence in type 2 diabetes: a systematic review and meta-analysis","volume":"20","author":"McGovern","year":"2018","journal-title":"Diabetes Obes. Metab"},{"key":"10.1016\/j.clml.2022.05.003_bib0024","unstructured":"Wells B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses 2014 Accessed from: http:\/\/www.ohri.ca\/programs\/clinical_epidemiolo, Accessed March 20, 2022."},{"key":"10.1016\/j.clml.2022.05.003_bib0025","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/jech-2013-203104","article-title":"Meta-analysis of prevalence","volume":"67","author":"Barendregt","year":"2013","journal-title":"J. Epidemiol. Community Health"},{"key":"10.1016\/j.clml.2022.05.003_bib0026","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ (Clinical research ed)"},{"key":"10.1016\/j.clml.2022.05.003_bib0027","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ (Clinical research ed)"},{"key":"10.1016\/j.clml.2022.05.003_bib0028","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.cegh.2018.05.005","article-title":"Interpretation of subgroup analyses in systematic reviews: a tutorial","volume":"7","author":"Richardson","year":"2018","journal-title":"Clin Epidemiol Glob Health"},{"key":"10.1016\/j.clml.2022.05.003_bib0029","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214446","article-title":"Adherence to immunomodulatory drugs in patients with multiple myeloma","volume":"14","author":"Cransac","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2022.05.003_bib0030","first-page":"186","article-title":"Medication adherence, health care utilization, and costs among patients initiating oral oncolytics for multiple myeloma or chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"26","author":"Dashputre","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.clml.2022.05.003_bib0031","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3111\/13696998.2015.1130710","article-title":"A retrospective study of direct cost to patients associated with the use of oral oncology medications for the treatment of multiple myeloma","volume":"19","author":"Lee","year":"2016","journal-title":"J Med Econ"},{"key":"10.1016\/j.clml.2022.05.003_bib0032","first-page":"1244","article-title":"Effect of a smart pill bottle and pharmacist intervention on medication adherence in patients with multiple myeloma new to lenalidomide therapy","volume":"25","author":"Mauro","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.clml.2022.05.003_bib0033","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.clml.2019.09.618","article-title":"Adherence to lenalidomide in older adults with newly diagnosed multiple myeloma","volume":"20","author":"Mian","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2022.05.003_bib0034","doi-asserted-by":"crossref","first-page":"S422","DOI":"10.1016\/j.jval.2020.08.148","article-title":"PCN11 non-adherence to oral treatments in patients with multiple myeloma: real-world evidence from a german claims data","volume":"23","author":"Kocaata","year":"2020","journal-title":"Value Health"},{"key":"10.1016\/j.clml.2022.05.003_bib0035","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.2217\/fon-2017-0727","article-title":"Treatment patterns and medication adherence among patients diagnosed with multiple myeloma and treated with panobinostat","volume":"14","author":"Chari","year":"2018","journal-title":"Future Oncol"},{"key":"10.1016\/j.clml.2022.05.003_bib0036","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1177\/1078155220980807","article-title":"Adherence to and effectiveness of lenalidomide after 1 year of treatment in a real world setting","volume":"28","author":"Santoleri","year":"2022","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.clml.2022.05.003_bib0037","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1007\/s00277-021-04543-7","article-title":"Oral therapy adherence and satisfaction in patients with multiple myeloma","volume":"100","author":"Solano","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2022.05.003_bib0038","article-title":"Adherence to pomalidomide in patients with multiple myeloma: a US-based claims study","volume":"36","author":"Gatwood","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.05.003_bib0039","first-page":"1457","article-title":"Treatment utilization patterns of newly initiated oral anticancer agents in a national sample of medicare beneficiaries","volume":"27","author":"Doshi","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.clml.2022.05.003_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/ecc.12413","article-title":"Faithfull S. Do patients on oral chemotherapy have sufficient knowledge for optimal adherence? A mixed methods study","volume":"26","author":"Arber","year":"2017","journal-title":"Eur J Cancer Care (Engl)"},{"key":"10.1016\/j.clml.2022.05.003_bib0041","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1177\/1078155221993528","article-title":"Adherence to thalidomide in patients with multiple myeloma: a cross-sectional study in a Brazilian metropolis","volume":"28","author":"Silveira","year":"2022","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.clml.2022.05.003_bib0042","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.651523","article-title":"Validation of an instrument for measuring adherence to treatment with immunomodulators in patients with multiple myeloma","volume":"12","author":"Silveira","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clml.2022.05.003_bib0043","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1136\/bjophthalmol-2016-308505","article-title":"Treatment patterns and medication adherence of patients with glaucoma in South Korea","volume":"101","author":"Kim","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.clml.2022.05.003_bib0044","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1182\/blood.V128.22.4504.4504","article-title":"Early discontinuation of lenalidomide in patients with relapsing or refractory multiple myeloma: predictive factors for stopping in the real life","volume":"128","author":"Pistone","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.05.003_bib0045","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1007\/s00520-019-04721-4","article-title":"High adherence of patients with multiple myeloma who receive treatment with immunomodulatory drugs (IMIDS) in hematology\/oncology group practices in Germany","volume":"27","author":"Feiten","year":"2019","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clml.2022.05.003_bib0046","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.e20031","article-title":"Factors associated with non-adherence to lenalidomide in patients with multiple myeloma","volume":"36","author":"Leng","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.05.003_bib0047","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1586\/14737140.2016.1159515","article-title":"Medication adherence to oral anticancer drugs: systematic review","volume":"16","author":"Huang","year":"2016","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.clml.2022.05.003_bib0048","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.2147\/PPA.S106629","article-title":"Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature","volume":"10","author":"Eek","year":"2016","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.clml.2022.05.003_bib0049","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/MLR.0b013e318032937e","article-title":"Health beliefs, disease severity, and patient adherence: a meta-analysis","volume":"45","author":"DiMatteo","year":"2007","journal-title":"Medical Care"},{"key":"10.1016\/j.clml.2022.05.003_bib0050","doi-asserted-by":"crossref","first-page":"618","DOI":"10.6004\/jnccn.2012.0063","article-title":"Oral chemotherapy program improves adherence and reduces medication wastage and hospital admissions","volume":"10","author":"Khandelwal","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2022.05.003_bib0051","first-page":"775","article-title":"New oral anti-cancer drugs and medication safety","volume":"116","author":"Schlichtig","year":"2019","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.clml.2022.05.003_bib0052","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ctrv.2017.05.002","article-title":"Adherence to oral cancer therapy in older adults: the international society of geriatric oncology (SIOG) taskforce recommendations","volume":"57","author":"Mislang","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clml.2022.05.003_bib0053","doi-asserted-by":"crossref","first-page":"76","DOI":"10.12701\/yujm.2018.35.1.76","article-title":"Chemotherapy adherence is a favorable prognostic factor for elderly patients with multiple myeloma who are treated with a frontline bortezomib-containing regimen","volume":"35","author":"Cho","year":"2018","journal-title":"Yeungnam Univ J Med"},{"key":"10.1016\/j.clml.2022.05.003_bib0054","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jgo.2016.07.010","article-title":"Polypharmacy and potentially inappropriate medication use in geriatric oncology","volume":"7","author":"Sharma","year":"2016","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.clml.2022.05.003_bib0055","first-page":"827","article-title":"Reducing inappropriate polypharmacy: the process of deprescribing","volume":"175","author":"Scott","year":"2015","journal-title":"AMA Intern Med"},{"key":"10.1016\/j.clml.2022.05.003_bib0056","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1186\/s13104-015-1231-8","article-title":"Adherence to oral anticancer chemotherapy: What influences patients' over or non-adherence? Analysis of the OCTO study through quantitative-qualitative methods","volume":"8","author":"Bourmaud","year":"2015","journal-title":"BMC Res Note"},{"key":"10.1016\/j.clml.2022.05.003_bib0057","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1200\/JCO.2013.52.9123","article-title":"Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia","volume":"32","author":"Dusetzina","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.05.003_bib0058","first-page":"1","article-title":"Financial toxicity of cancer care: it's time to intervene","volume":"108","author":"Zafar","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clml.2022.05.003_bib0059","first-page":"21","article-title":"Copayments: too much, yet not enough?","volume":"3","author":"Silverman","year":"2006","journal-title":"Biotechnol Healthc"},{"key":"10.1016\/j.clml.2022.05.003_bib0060","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1634\/theoncologist.2012-0279","article-title":"The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience","volume":"18","author":"Zafar","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2022.05.003_bib0061","first-page":"19","article-title":"Developing an intervention for cancer patients prescribed oral chemotherapy: a generic patient diary","author":"Oakley","year":"2010","journal-title":"Eur J Cancer Care"},{"key":"10.1016\/j.clml.2022.05.003_bib0062","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.clinthera.2012.04.007","article-title":"Impact of a text messaging pilot program on patient medication adherence","volume":"34","author":"Foreman","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.clml.2022.05.003_bib0063","first-page":"549","article-title":"A motivational interviewing intervention by pharmacy students to improve medication adherence","volume":"23","author":"Abughosh","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.clml.2022.05.003_bib0064","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3322\/caac.20004","article-title":"Patient adherence and persistence with oral anticancer treatment","volume":"59","author":"Ruddy","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2022.05.003_bib0065","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2147\/PPA.S36195","article-title":"Words that make pills easier to swallow: a communication typology to address practical and perceptual barriers to medication intake behavior","volume":"6","author":"Linn","year":"2012","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.clml.2022.05.003_bib0066","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.pec.2016.01.020","article-title":"Health literacy and adherence to medical treatment in chronic and acute illness: a meta-analysis","volume":"99","author":"Miller","year":"2016","journal-title":"Patient Educ Couns"},{"key":"10.1016\/j.clml.2022.05.003_sbref0067","series-title":"Caregiver Role in Adherence in Oral Oncology Care Coordination","year":"2021"},{"key":"10.1016\/j.clml.2022.05.003_bib0068","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.soncn.2011.02.005","article-title":"Interventions to promote adherence with oral agents","volume":"27","author":"Schneider","year":"2011","journal-title":"Semin Oncol nursing"},{"key":"10.1016\/j.clml.2022.05.003_bib0069","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/jnci\/djz244","article-title":"Interventions to enhance adherence to oral antineoplastic agents: a scoping review","volume":"112","author":"Rosenberg","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clml.2022.05.003_bib0070","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1016\/j.sapharm.2021.04.011","article-title":"A systematic scoping review of interventions to optimise medication prescribing and adherence in older adults with cancer","volume":"18","author":"Murphy","year":"2022","journal-title":"Res Social Adm Pharm"},{"key":"10.1016\/j.clml.2022.05.003_bib0071","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1016\/j.jval.2021.04.248","article-title":"PCN156 real-world non-persistence with oral multiple myeloma treatments: a comparative analysis of methodologies using claims data","volume":"24","author":"Kocaata","year":"2021","journal-title":"Value Health"},{"key":"10.1016\/j.clml.2022.05.003_bib0072","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s13142-015-0315-2","article-title":"Self-report measures of medication adherence behavior: recommendations on optimal use","volume":"5","author":"Stirratt","year":"2015","journal-title":"Transl Behav Med"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022001689?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022001689?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T11:47:14Z","timestamp":1729856834000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022001689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":72,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S2152265022001689"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.05.003","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real World Adherence to and Persistence With Oral Oncolytics in Multiple Myeloma: A Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}